AEGiS-ATDN: PEG-Intron

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

PEG-Intron

Information Bulletin #15 - May 2002

PEG-Intron is now available as an approved drug, it is expected that some doctors will prescribe the combination of PEG-Intron and Rebetol for people who are co-infected. In order to get a prescription for PEG-Intron patients must enroll in the Schering sponsored Access Assurance program and receive an ID number and card. Unless you are a registered Access Assurance program member, you will not be able to fill a prescription for PEG-Intron.

Because of the number of people who have enrolled in the program so far, and the limited availability of PEG-Intron, a wait list began in mid-January. Schering anticipated by April that there should be a more steady supply of the drug, as they become better able to calculate ongoing demand for the drug, but that has not yet happened. We have not yet received official word that the programs new or a greater number of slots available for people interested in taking the drug. Once you receive the ID card, you take it to a pharmacy, where the pharmacist gets an authorization number to fill the prescription. This could take up to five days. You have the option of providing contact information when enrolling in the program. If you chose this option, someone from a Schering-Plough contracted consulting firm will contact you if you haven't refilled your prescription within a 60 day period. You will also have a 12 month supply of the drug set aside for you. If you don't refill your prescription within 60 days of receiving the drug, you will need to reapply to the program. The Schering-Plough Access Assurance ID# phone number (toll-free) is 1-888-437-2608.

020510
TR020508

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .